← Back to Search

Cancer Vaccine

Poly-ICLC (Cohort B) for Prostate Cancer (PORTER Trial)

Phase 1
Waitlist Available
Research Sponsored by Parker Institute for Cancer Immunotherapy
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Provide fresh pre-treatment core needle or incisional biopsy of a metastatic tumor lesion not previously irradiated. Fine needle aspiration is not acceptable.
Additionally, if a pre-treatment biopsy is not medically feasible for participants with bone only disease, formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 10 slides containing unstained, freshly cut, serial sections must be provided.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2.5 years
Awards & highlights

PORTER Trial Summary

This trial will look at different combinations of immunotherapy to see if they are safe and effective in treating prostate cancer that has spread and is resistant to hormone therapy.

Eligible Conditions
  • Prostate Cancer

PORTER Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

PORTER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of adverse events
Secondary outcome measures
Disease control rate
Objective response rate (ORR)
Overall survival (OS)
+2 more

PORTER Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort C: CDX-301 + INO-5151 + NivolumabExperimental Treatment4 Interventions
Group II: Cohort B: SBRT + CDX-301 + Poly-ICLC + NivolumabExperimental Treatment4 Interventions
Group III: Cohort A: NKTR-214 + NivolumabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cellectra 2000
2019
Completed Phase 1
~50
CDX-301 (Cohort B and C)
2019
Completed Phase 1
~50
Poly-ICLC (Cohort B)
2019
Completed Phase 1
~50
Stereotactic body radiation therapy (SBRT) (Cohort B)
2019
Completed Phase 1
~50
INO-5151 (Cohort C)
2019
Completed Phase 1
~50
Nivolumab (Cohort A, B and C)
2019
Completed Phase 1
~50
NKTR-214 (Cohort A)
2019
Completed Phase 1
~50

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,629 Previous Clinical Trials
4,126,273 Total Patients Enrolled
42 Trials studying Prostate Cancer
5,447 Patients Enrolled for Prostate Cancer
Celldex TherapeuticsIndustry Sponsor
60 Previous Clinical Trials
3,801 Total Patients Enrolled
1 Trials studying Prostate Cancer
2 Patients Enrolled for Prostate Cancer
Cancer Research Institute, New York CityOTHER
20 Previous Clinical Trials
1,256 Total Patients Enrolled
1 Trials studying Prostate Cancer
58 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
~7 spots leftby Mar 2025